skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Zach McLellan & Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including analysis on Allogene's announcement that they are in-licensing the TALEN technology from Pfizer to commericalise and develop allogeneic, potentially leading to a strong acceleration of CART therapies.

Topics covered in this episode include:

  • Allogene in-licenses TALEN (originally developed by Cellectis) technology from Pfizer (CLLS PFE) - 0:30
  • New data for NeuVax/Herceptin combination in breast cancer (SLS RHHBY)- 10:45
  • MediciNova announces early termination of Phase 2 trial of MN-001 in NASH/NAFLD based on positive data (MNOV) - 17:40

Subscribe to this podcast here



Next steps



  • 日本:         +81 3 6273 4260
  • 米国 (無料):+1 888 670 8900
  • 米国 (有料):+1 908 547 2200
  • 英国&欧州:+44 (20) 337 73737
  • 豪:      +61 2 8705 6907